Chengyuan Zhang

Chengyuan Zhang

Auto-generated profile, based on publicly available information

Chengyuan Zhang

Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, Rehabilitation School, Kunming Medical University, Kunming, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CZChengyuan Zhang
Chengyuan Zhang
LLLing Long
Ling Long
YXYao Xiong
Yao Xiong
CWChenping Wang
Chenping Wang
CPCuiping Peng
Cuiping Peng
XLXiaohui Li
Xiaohui Li

10 January 2025 in Advanced Science
Verified
Journal Article
Open access
CZChengyuan Zhang
Chengyuan Zhang
YYYuchuan Yuan
Yuchuan Yuan
QXQiong Xia
Qiong Xia
JWJunjie Wang
Junjie Wang
KXKangkang Xu
Kangkang Xu
XZXing Zhou
Xing Zhou
Small molecules as nanomedicine carriers offer advantages in drug loading and preparation. Selecting effective small molecules for stable nanomedicines is challenging. This study used artificial intelligence (AI) to screen drug combinations for self‐assembling nanomedicines, employing physiochemical parameters to predict formation via machine learning. Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs) are identified as effective carriers for antineoplastic drugs, with high drug loading. Nanomedicines, PEG‐coated indomethacin/paclitaxel nanomedicine (PiPTX), and laminarin‐modified indomethacin/paclitaxel nanomedicine (LiDOX), are developed with extended circulation and active targeting functions. Indomethacin/paclitaxel nanomedicine iDOX exhibits pH‐responsive drug release in the tumor microenvironment. These nanomedicines enhance anti‐tumor effects and reduce side effects, offering a rapid approach to clinical nanomedicine development.

16 November 2020 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
YYYuchuan Yuan
Yuchuan Yuan
LLLing Long
Ling Long
JLJiaxing Liu
Jiaxing Liu
YLYongyao Lin
Yongyao Lin
CPCuiping Peng
Cuiping Peng
XZXing Zhou
Xing Zhou
Background: Monocyte/macrophage-targeting delivery systems (MTDSs) have been focused upon as an emerging routine for delivering drugs to treat various macrophage-related diseases. However, the ability of MTDSs to distinguish different macrophage-related diseases and their impact on macrophage function and disease progression have not been systematically revealed, which is important for actively targeted therapeutic or diagnostic strategies.Results: Herein, we used dextran-modified polystyrene nanoparticles (DEX-PS) to demonstrate that modification of nanoparticles by dextran can specifically enhance their recognition by M2 macrophages in vitro, but it is obstructed by monocytes in peripheral blood according to in vivo assays. DEX-PS not only targeted and became distributed in tumors, an M2 macrophage-related disease, but was also highly distributed in an M1 macrophage-related disease, namely acute peritonitis. Thus, DEX-PS acts as a double-edged sword in these two different diseases by reeducating macrophages to a pro-inflammatory phenotype.Conclusions: Our results suggest that MTDSs, even those designed based on differential expression of receptors on specific macrophage subtypes, lack the ability to distinguish different macrophage subtype-related diseases in vivo. In addition to the potential impact of these carrier materials on macrophage function, studies of MTDSs should pay greater attention to the distribution of nanoparticles in non-target macrophage-infiltrated disease sites and their impact on disease processes.

21 March 2025 in Science Advances
Verified
Journal Article
Open access
QZQing Zhang
Qing Zhang
YSYan Shen
Yan Shen
CZChengyuan Zhang
Chengyuan Zhang
HZHanyi Zhang
Hanyi Zhang
XLXuemei Li
Xuemei Li
XZXing Zhou
Xing Zhou
Acute organ injuries represent a major public health concern, driven by inflammation and mitochondrial dysfunction, leading to cell damage and organ failure. In this study, we engineered neutrophil membrane–fused mitochondria (nMITO), which combine the injury-targeting and anti-inflammatory properties of neutrophil membrane proteins with the cell repairing function of mitochondria. nMITO effectively blocked inflammatory cascades and restored mitochondrial function, targeting both key mechanisms in acute organ injuries. In addition, nMITO selectively targeted damaged endothelial cells via β-integrins and were delivered to injured tissues through tunneling nanotubes, enhancing their regulatory effects on inflammation and cell damage. In mouse models of acute myocardial injury, liver injury, and pancreatitis, nMITO notably reduced inflammatory responses and repaired tissue damage. These findings suggest that nMITO is a promising therapeutic strategy for managing acute organ injuries.

27 October 2021 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
ASAnjie Shi
Anjie Shi
LLLing Long
Ling Long
ZLZhibin Liu
Zhibin Liu
YLYao Liu
Yao Liu
QGQingjia Gong
Qingjia Gong
XZXing Zhou
Xing Zhou
Nanomedicines typically use polymeric materials or liposomes as carriers. This provides targeting advantages but may lead to a series of defects, such as low drug loading, high risk in terms of safety, and high production costs. Herein, we report a computer simulation-assisted designing method for the construction of a novel doxorubicin (DOX) nanomedicine without any polymer carriers. We used a small molecular drug, bindarit (BIN), as a carrier of DOX to provide synergistic antitumor effects. First, the intermolecular forces between DOX and BIN were calculated for evaluating the interaction and potential conformation of the DOX/BIN complex. Then, the potential assembly ability of the DOX/BIN complex was predicated here by using dissipative particle dynamic stimulation. These computational simulation results suggested that BIN could form an amphiphilic complex with DOX through ππ stacking, hydrogen bonding, and electrostatic interaction and then self-assemble to nanoaggregates at the mesoscopic scale. Under the computational guidance, doxorubicin/bindarit nanoparticles (DOX/BIN NPs) in a spherical morphology were successfully prepared, and these NPs possess the original cytotoxic activity of DOX. Thus, this multiscale computer simulation-assisted design strategy can serve as an effective approach to develop nanomedicines using small molecules as a carrier.

3 October 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
PWPan Wang
Pan Wang
LLLing Long
Ling Long
WZWeiya Zeng
Weiya Zeng
LMLufan Mei
Lufan Mei
ZTZihao Tian
Zihao Tian
XZXing Zhou
Xing Zhou
PD-1/PD-L1 blockade benefits patients across > 20 cancer types, yet durable responses remain limited and antibody therapies only transiently engage the axis while causing systemic immune-related adverse events. We report lipoRDPA, a rationally designed liposomal degrader that fuses MMP-9-responsive gating with PD-L1-targeted protein degradation (TPD) into a single unified mechanism. The platform conjugates anti-PD-L1 antibody atezolizumab (DPA) onto a liposome and shields it with an MMP-9-cleavable PEG cloak, so that PD-L1 binding, internalization, and lysosomal degradation are activated only in the protease-rich TME while staying silent in circulation. Crucially, the MMP-9 gate and the degrader form one mechanism: unlike classical enzyme-gated carriers that cleave to release an entrapped payload, the cloak is the switch that confines an intrinsically active degradation effector to the tumor—the central challenge of nanobody-targeted protein degradation. In vitro, lipoRDPA exhibits PD-L1-dependent binding and degrades both surface and total PD-L1 through targeted degradation, circumventing receptor recycling and ligand competition to sustain T-cell activation beyond blockade. In vivo imaging confirms reduced off-target distribution and enriched tumor accumulation. In human-T-cell-reconstituted NSG mice, lipoRDPA enhances intratumoral CD8⁺ T-cell infiltration, suppresses Ki-67, and yields the strongest tumor growth inhibition. In immunocompetent BALB/c mice, the murine counterpart lipoRDPa similarly inhibits tumors while preserving normal lung PD-L1 and avoiding the pulmonary inflammation seen with constitutively exposed formulations. By fusing TME-gated activation with a PD-L1-targeted degrader into one tumor-gated mechanism, lipoRDPA confines checkpoint elimination to the tumor, reconciling antitumor efficacy with tissue-level biosafety and providing a generalizable strategy for tumor-gated targeted protein degradation immunotherapy.